The $195M PRV sale provides a meaningful cash runway extension without dilution. Monitor for pipeline catalysts (DNL126, DNL593, DNL952) and any updates on the HSR clearance timeline. The cash strengthens Denali's ability to advance its clinical programs, but execution risk remains.
DNLI drugs
DNLI drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 18 $23.31entry
- T+1 · 5mo ago +3.17%α +3.49% · $24.05
- T+5 · 5mo ago +6.09%α +7.76% · $24.73
- T+20 · 4mo ago −2.49%α −3.02% · $22.73
- T+60 · 2mo ago −8.97%α −10.86% · $21.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Denali Therapeutics announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million in gross proceeds. The PRV was awarded following FDA approval of AVLAYAH for Hunter syndrome in March 2026. The non-dilutive cash infusion strengthens Denali's financial flexibility and will fund its clinical pipeline, including programs for lysosomal storage disorders and neurodegenerative diseases.
Key Financial Metrics
Key Facts
- Denali entered a definitive agreement to sell its Rare Pediatric Disease PRV for $195 million gross proceeds.
- The PRV was awarded after FDA accelerated approval of AVLAYAH (tividenofusp alfa-eknm) for Hunter syndrome in March 2026.
- Proceeds will support Denali's TransportVehicle-enabled clinical pipeline, including DNL126, DNL593, DNL952, and DNL628.
- The transaction is subject to customary closing conditions, including HSR Act waiting period expiration.
Financial Impact
$195 million non-dilutive cash infusion, representing ~5.3% of Denali's $3.7B market cap.
Risk Factors
- PRV sale is subject to HSR waiting period and customary closing conditions.
- Pipeline programs are still in clinical/IND-enabling stages with no guarantee of success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3314101 |
Track record
17 reports on DNLI
2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +23.19% at T+60 after the May 7, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.75 Now $18.08 −3.55% settles Nov 17
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $20.96 to $19.72 Now $18.08 −13.74% ▼ −5.92% −1.51% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $18.94 to $18.86 Now $18.08 −4.54% ▼ −0.42% +0.06% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $18.66 Now $18.08 −3.11% No price data
- Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $21.40 to $21.09 Now $18.08 −15.51% ▼ −1.45% −2.30% vs SPY
- Sep 4, 202610w ago Insider Cluster Neutral 2/10 Entry $22.08 to $21.57 Now $18.08 −18.12% ▼ −2.31% −1.84% vs SPY
- Aug 6, 202614w ago 8-K Mixed 6/10 Entry $24.83 to $25.00 Now $18.08 −27.18% ▲ +0.68% +0.71% vs SPY
- Jul 27, 202616w ago Press Release Neutral 1/10 Entry $24.05 Now $18.08 −24.82% No price data
- Jun 18, 202621w ago 8-K Bullish 6/10 Entry $23.31 to $24.05 Now $18.08 −22.44% ▲ +3.17% +3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers